This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Andreas et al1 for publishing the results of their pilot study comparing dabigatran etexilate with phenprocoumon in patients with a left ventricular assist device.
The authors selected a dabigatran dose of 110 mg twice daily (BID) for patients with normal renal function (creatinine clearance >80 mL/min; n=2) and 75 mg BID for patients with impaired renal function (creatinine clearance 30–80 mL/min; n=6) and observed an excess of thromboembolic events with dabigatran compared with phenprocoumon. They state that “The dose administered…was in accordance with the recommended dose for atrial fibrillation as of 2010 and based on the RE-LY study results” and also that “Dabigatran dosages…adhered to the recommended dosage …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Article Tools
Share this Article
- Letter by Heinrich-Nols and Kreuzer Regarding Article, “Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial”
